CorEvitas registry data shows H2H comparison of 369 CCP+ abatacept & 475 CCP+ tofacitinib treated patients showed equivalent drug responses (reduced CDAI or PRO's); b/tsDMARD naive pts had numerically better ABA response at 6 mos (P = 0.662) https://t.co/36jr7l2DKm https://t.co/PItYrvMUNV